One mechanism that may be compromising the efficacy of CD47-blocking therapy is the immunosuppressive tumor microenvironment (TME) which is rich in signals that polarize tumor-associated macrophages (TAMs) towards a pro-tumorigenic M2 phenotype17. Here, CD47 is linked to neoplasm.